Depression, Insomnia
Conditions
Keywords
Pregnancy, Postpartum, Telemedicine, Cognitive arousal, Insomnia, Depression, Mindfulness
Brief summary
Nearly half of women develop insomnia during pregnancy, which is associated with increased risk for developing perinatal depression. The purpose of this research is to evaluate the implementability and effectiveness of a mindfulness-based therapy for insomnia relative to cognitive-behavioral therapy for insomnia in pregnant women with insomnia and comorbid depression. The investigators aim to examine whether a mindfulness-based intervention effectiveness reduces symptoms of insomnia and comorbid depression.
Detailed description
The investigators will conduct a pilot hybrid type 1 effectiveness-implementation randomized controlled trial (RCT) wherein 100 pregnant women with DSM-5 insomnia disorder and comorbid depression (Edinburgh Postnatal Depression Scale ≥ 10) are randomized to a mindfulness-based intervention--Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)--or Cognitive Behavioral Therapy for Insomnia (CBTI). Patients will be recruited from women's health clinics across Henry Ford Health in Metro Detroit including underserved women, serving as real-world implementation. Per clinic operations since the pandemic, therapies will be via telemedicine to meet patient expectations. Study outcomes will be assessed before and after treatment, then across the first postpartum year.
Interventions
cognitive and behavioral treatment for perinatal insomnia.
Mindfulness and behavioral based therapy for perinatal insomnia.
Sponsors
Henry Ford Health System
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
1. Singleton pregnancy, gestational week 14-31. 2. DSM-5 Insomnia Disorder (acute or chronic). 3. Insomnia Severity Index (ISI) score ≥ 11. 4. Edinburgh Postnatal Depression Scale (EPDS) score ≥ 10. 5. Ensure adequate sleep opportunity. 6. Age ≥ 18, English-speaking. 7. Reliable internet access (treatment, assessments)
Exclusion criteria
1. High risk pregnancy (age \>40y, pre-eclampsia, any condition deemed serious risk to mother/fetus; hypertension and diabetes allowed). 2. Active suicidal intent (ideation is allowed). 3. Night or rotating shift work. 4. Epworth Sleepiness Scale\>15 (Excessive sleepiness) 5. Health condition unsafe for sleep restriction (bipolar, epilepsy, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparative effectiveness between PUMAS and CBTI on acute insomnia effects. | The investigators will examine change in ISI scores from Pretreatment Baseline to Posttreatment, the latter will occur 6-9 weeks after Baseline. | The Insomnia Severity Index (ISI) is a commonly used self-report measure of insomnia symptoms that has been validated in a perinatal sample. The ISI scores range from 0-28 with higher scores indicating greater insomnia severity. |
| Comparative effectiveness between PUMAS and CBTI on postpartum insomnia effects. | The investigators will examine changes in ISI scores across the first postnatal year, which will be assessed at 3, 6, 9, and 12 months postpartum.. | The Insomnia Severity Index (ISI) is a commonly used self-report measure of insomnia symptoms that has been validated in a perinatal sample. The ISI scores range from 0-28 with higher scores indicating greater insomnia severity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparative effectiveness between PUMAS and CBTI on acute depression effects. | The investigators will examine change in EPDS scores from Pretreatment Baseline to Posttreatment, the latter will occur 6-9 weeks after Baseline. | The Edinburgh Postnatal Depression Scale (EPDS) is the most widely used depression measure in both pregnant and postnatal women. It is validated for use in clinical trials. The EPDS scores range from 0-30 with higher scores indicating greater depression severity. |
| Comparative effectiveness between PUMAS and CBTI on postpartum depression effects. | The investigators will examine changes in EPDS scores across the first postnatal year, which will be assessed at 3, 6, 9, and 12 months postpartum. | The Edinburgh Postnatal Depression Scale (EPDS) is the most widely used depression measure in both pregnant and postnatal women. It is validated for use in clinical trials. The EPDS scores range from 0-30 with higher scores indicating greater depression severity. |
| Comparative effectiveness between PUMAS and CBTI on acute cognitive arousal effects. | The investigators will examine change in PSASC scores from Pretreatment Baseline to Posttreatment, the latter will occur 6-9 weeks after Baseline. | The Pre-Sleep Arousal Scale's Cognitive factor (PSASC) is a self-report measure of nocturnal cognitive arousal that has been validated in the perinatal population. Scores range form 8-40 with higher scores indicating greater nighttime cognitive arousal. |
| Comparative effectiveness between PUMAS and CBTI on postpartum cognitive arousal effects. | The investigators will examine changes in PSASC scores across the first postnatal year, which will be assessed at 3, 6, 9, and 12 months postpartum. | The Pre-Sleep Arousal Scale's Cognitive factor (PSASC) is a self-report measure of nocturnal cognitive arousal that has been validated in the perinatal population. Scores range form 8-40 with higher scores indicating greater nighttime cognitive arousal. |
Countries
United States
Outcome results
None listed